{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:37:59Z","timestamp":1786649879798,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>\n                    A\n                    <jats:sc>BSTRACT<\/jats:sc>\n                  <\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose\/background:<\/jats:title>\n                    <jats:p>With the rising global prevalence of type 2 diabetes mellitus (T2DM), effective treatment strategies are essential. Sodium\u2013glucose cotransporter-2 (SGLT2) inhibitors, key in T2DM management, offer benefits beyond glycemic control. This study aimed to assess global research trends, hotspots, and future directions of SGLT2 inhibitor studies in T2DM through bibliometric analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>English-language publications on SGLT2 inhibitors in T2DM (2014\u20132024) were retrieved from the Web of Science Core Collection. Bibliometric techniques were applied to analyze publication output, geographic distributions, institutional contributions, and citation patterns. Visualization and network analyses were conducted using VOSviewer (v1.6.19) and CiteSpace (v6.3.1.0).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 4,146 publications were identified. The USA led in research output (1,152 publications), followed by Japan (857) and China (792). Annual publications grew steadily. Keyword and citation analyses revealed a shift in research focus from glycemic control to cardiovascular and renal protection. The most cited paper, Dapagliflozin and Cardiovascular Outcomes (3,842 citations), emphasized the cardiovascular benefits of SGLT2 inhibitors, reflecting the evolving \u201cprevention\u2013treatment integration\u201d approach in diabetes care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This analysis provides a comprehensive overview of global SGLT2 inhibitor research in T2DM. The findings highlight the transition from metabolic control to cardiorenal protection, guiding future research and clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jfmpc.jfmpc_1619_25","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T13:00:47Z","timestamp":1767013247000},"page":"4967-4975","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Bibliometric analysis of research hotspots and trends of type 2 diabetes mellitus and sodium\u2013glucose cotransporter-2 inhibitors"],"prefix":"10.4103","volume":"14","author":[{"given":"Bai","family":"Qiuyu","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, Graduate School of Hebei North University, Zhangjiakou City, Hebei Province, China"},{"name":"Department of Endocrinology, Hebei General Hospital, Shijiazhuang City, Hebei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Xian","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Hebei General Hospital, Shijiazhuang City, Hebei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Jinhu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Hebei General Hospital, Shijiazhuang City, Hebei Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"key":"R1-20251230","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas:Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"R2-20251230","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12091958","article-title":"Management of microcomplications of diabetes mellitus:Challenges, current trends, and future perspectives in treatment","volume":"12","author":"Yapislar","year":"2024","journal-title":"Biomedicines"},{"key":"R3-20251230","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.diabres.2012.04.017","article-title":"Association of KCNJ11 E23K gene polymorphism with hypoglycemia in sulfonylurea-treated Type 2 diabetic patients","volume":"98","author":"Ragia","year":"2012","journal-title":"Diabetes Res Clin Pract"},{"key":"R4-20251230","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3390\/ijms23073651","article-title":"An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors","volume":"23","author":"Salvatore","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R5-20251230","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jacc.2024.06.016","article-title":"Kidney and cardiovascular effectiveness of SGLT2 inhibitors vs GLP-1 receptor agonists in type 2 Diabetes","volume":"84","author":"Edmonston","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"R6-20251230","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.118.037778","article-title":"Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-Reg outcome trial","volume":"139","author":"Fitchett","year":"2019","journal-title":"Circulation"},{"key":"R7-20251230","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S0735-1097(24)02368-4","article-title":"Soluble suppression of tumorigenicity 2 (SST2) and cardiovascular outcomes in persons with type 2 diabetes mellitus randomized to dapagliflozin or placebo:Analyses from the DECLARE-TIMI 58 trial","volume":"83","author":"Haller","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"R8-20251230","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.2337\/dc21-0300","article-title":"Efficacy and safety of dapagliflozin by baseline glycemic status:A prespecified analysis from the DAPA-CKD trial","volume":"44","author":"Persson","year":"2021","journal-title":"Diabetes Care"},{"key":"R9-20251230","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/S40037-021-00695-4","article-title":"Bibliometrics:Methods for studying academic publishing","volume":"11","author":"Ninkov","year":"2022","journal-title":"Perspect Med Educ"},{"key":"R10-20251230","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3389\/fnins.2024.1434756","article-title":"Bibliometric and visualized analysis of 2014-2024 publications on therapy for diabetic peripheral neuropathy","volume":"18","author":"Fu","year":"2024","journal-title":"Front Neurosci"},{"key":"R11-20251230","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/MD.0000000000036478","article-title":"Bibliometrics and visual analysis of metformin and gut microbiota from 2012 to 2022:A systematic review","volume":"102","author":"Shu","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"R12-20251230","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/MD.0000000000039295","article-title":"Global hotspots and trends in diabetic peripheral neuropathy research from 2011 to 2023","volume":"103","author":"Tang","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"R13-20251230","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jtv.2025.100854","article-title":"Critical analysis of hot topics in diabetic nephropathy related experimental research:A bibliometric analysis from 2018 to 2024","volume":"34","author":"Jia","year":"2025","journal-title":"J Tissue Viability"},{"key":"R14-20251230","doi-asserted-by":"crossref","first-page":"5613","DOI":"10.1007\/s11192-022-04475-7","article-title":"Combining web of science and scopus datasets in citation-based literature study","volume":"127","author":"Kumpulainen","year":"2022","journal-title":"Scientometrics"},{"key":"R15-20251230","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s11192-009-0146-3","article-title":"Software survey:VOSviewer, a computer program for bibliometric mapping","volume":"84","author":"van","year":"2010","journal-title":"Scientometrics"},{"key":"R16-20251230","first-page":"1","article-title":"Science mapping:A systematic review of the literature","volume":"2","author":"Chen","year":"2017","journal-title":"J Data Inf Sci"},{"key":"R17-20251230","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/MD.0000000000040388","article-title":"Global research trends of virtual simulation technology in public health education and training:A visual analysis based on CiteSpace and VOSviewer","volume":"103","author":"Dong","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"R18-20251230","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejim.2022.03.031","article-title":"Sodium glucose cotransporter-2 inhibitors protect the cardiorenal axis:Update on recent mechanistic insights related to kidney physiology","volume":"100","author":"van","year":"2022","journal-title":"Eur J Intern Med"},{"key":"R19-20251230","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1093\/ndt\/gfae106","article-title":"The long-term effects of dapagliflozin in chronic kidney disease:a time-to-event analysis","volume":"39","author":"McEwan","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"R20-20251230","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.124.069568","article-title":"Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes:A SMART-C collaborative meta-analysis","volume":"149","author":"Patel","year":"2024","journal-title":"Circulation"},{"key":"R21-20251230","doi-asserted-by":"crossref","first-page":"728089","DOI":"10.3389\/fmed.2021.728089","article-title":"Effects of SGLT2 inhibitors on renal outcomes in patients with chronic kidney disease:A meta-analysis","volume":"8","author":"Li","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"R22-20251230","first-page":"8","article-title":"SGLT2 inhibitors in diabetic patients with cardiovascular disease or at high cardiovascular risk:A systematic review and meta-analysis of randomized controlled trials","volume":"9","author":"Zhao","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"R23-20251230","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2147\/IJNRD.S268811","article-title":"SGLT2 inhibitors:Emerging roles in the protection against cardiovascular and kidney disease among diabetic patients","volume":"13","author":"Vasquez-Rios","year":"2020","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"R24-20251230","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/0886022X.2023.2272717","article-title":"Upregulation of the protein kinase Lyn is associated with renal injury in type 2 diabetes patients","volume":"45","author":"Chen","year":"2023","journal-title":"Ren Fail"},{"key":"R25-20251230","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1515\/jom-2020-0153","article-title":"SGLT2 inhibitors:A narrative review of efficacy and safety","volume":"121","author":"Nelinson","year":"2021","journal-title":"J Osteopath Med"},{"key":"R26-20251230","doi-asserted-by":"crossref","first-page":"225","DOI":"10.56782\/pps.240","article-title":"Sodium-glucose cotransporter 2 inhibitors in heart failure","volume":"22","author":"Kazmierski","year":"2024","journal-title":"Prospect Pharm Sci"}],"container-title":["Journal of Family Medicine and Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_1619_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:59:29Z","timestamp":1786647569000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_1619_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_1619_25","relation":{},"ISSN":["2249-4863","2278-7135"],"issn-type":[{"value":"2249-4863","type":"print"},{"value":"2278-7135","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"2025-09-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}